| Literature DB >> 25516787 |
Wieslaw M Kazmierski1, Susan Danehower1, Maosheng Duan1, Robert G Ferris1, Vassil Elitzin1, Douglas Minick1, Matthew Sharp1, Eugene Stewart1, Manon Villeneuve1.
Abstract
We recently reported the discovery of preclinical CCR5 inhibitor GSK214096, 1 (J. Med. Chem. 2011, 54, 756). Detailed characterization of 1 revealed that it exists as a mixture of four separable atropisomers A-D. The two slow-interconverting pairs of rotamers A + B and C + D were separated and further characterized. HIV and CCR5-mediated chemotaxis data strongly suggest that the antiviral potency of 1 is due to rotamers A + B and not C + D. Furthermore, integrated UV, vibrational circular dichroism VCD and computational approach allowed to determine the M chirality in C + D (and P chirality in A + B). These findings imply additional avenues to be pursued toward new CCR5 antagonists.Entities:
Keywords: CCR5; GSK214096; HIV inhibitor; antagonist; atropisomer; chemokine; entry inhibitor
Year: 2014 PMID: 25516787 PMCID: PMC4265823 DOI: 10.1021/ml5004124
Source DB: PubMed Journal: ACS Med Chem Lett ISSN: 1948-5875 Impact factor: 4.345